EARS

Altamira Therapeutics Ltd. [EARS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

EARS Stock Summary

In the News

09:00 29 Nov 2023 EARS

Auris Medical Announces Launch of New Corporate Website

Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. The new website features a streamlined and modern design and also reflects the Company's recently announced strategic repositioning.

03:58 29 Nov 2023 EARS

5 Reddit Penny Stocks to Watch That Are Moving Right Now

Are these Reddit penny stocks worth adding to your small-caps watchlist right now? The post 5 Reddit Penny Stocks to Watch That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:40 29 Nov 2023 EARS

Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19

Auris Medical Holding Ltd (NASDAQ: EARS) has announced additional preclinical data in a primary human nasal airway epithelium model from its Bentrio (AM-301) nasal spray for COVID-19. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.

09:00 29 Nov 2023 EARS

Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2

Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. The manuscript describing these preclinical data is available on a preprint server at https://www.biorxiv.org/content/10.1101/2021.07.12.452021v1 and will undergo scientific peer-review for potential publication.

08:30 29 Nov 2023 EARS

Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany

Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries.

09:28 29 Nov 2023 EARS

EARS Stock Price Increases Over 14% Pre-Market

The stock price of Auris Medical Holding Ltd. (NASDAQ: EARS) increased by over 14% pre-market.

09:17 29 Nov 2023 EARS

Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs

Auris Medical Holding Ltd (NASDAQ: EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77 million common shares, the assumption of certain selling shareholders' cash outlays, as well as a future share-based payment contingent on reaching a specific development milestone.

08:51 29 Nov 2023 EARS

EARS Stock Price: Over 9% Increase Pre-Market Explanation

The stock price of Auris Medical Holding Ltd (NASDAQ: EARS) increased by over 9% pre-market. This is why it happened.

08:30 29 Nov 2023 EARS

Auris Medical Holding to Present at LD Micro Invitational XI Conference

Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com.

08:30 29 Nov 2023 EARS

Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo

Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it has reached the midpoint for enrollment in Part B of its Phase 2 proof-of-concept trial of AM-125 (intranasal betahistine) in the treatment of acute peripheral vertigo.

EARS Financial details

Company Rating
Buy
Market Cap
4.21M
Income
9.65M
Revenue
1.45M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
31 Mar 2021
P/E
-2.05
Forward P/E
-
PEG
-0.24
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
-
Current Ratio
-
Debt / Equity
-1.9
LT Debt / Equity
-0.67
-
-
EPS (TTM)
-48.52
EPS next Y
-
EPS next Q
-
EPS this Y
10.93%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-36.81%
Revenue last 5Y
-24.74%
Revenue Q/Q
-523.21%
EPS Q/Q
-52.17%
-
-
-
-
SMA20
-40%
SMA50
-50%
SMA100
-
Inst Own
35.89%
Inst Trans
0.76%
ROA
-
ROE
-
ROC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
1.38M
Shs Float
1M
-
-
-
-
Target Price
-
52W Range
3.0004-3.09
52W High
+1.5%
52W Low
+1.5%
RSI
29
Rel Volume
0.09
Avg Volume
1.89M
Volume
174.07K
Perf Week
8.36%
Perf Month
-42.87%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
1.40479
-
-
Volatility
0.18%, 1.09%
Prev Close
23.28%
Price
3.045
Change
19.88%

EARS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
31.85-0.390.580.10.34
Net income per share
-289.2-45.6-27.27-26.26-29.13
Operating cash flow per share
-332.87-57.71-16.11-20.64-9.53
Free cash flow per share
-380.44-78.46-23.81-25.67-11.89
Cash per share
135.679.5237.441.490.02
Book value per share
91.8141.555.7719.18-9.13
Tangible book value per share
2.88-5.0225.45-2.43-13.41
Share holders equity per share
91.8141.555.7719.18-9.13
Interest debt per share
63.030.22.191.167.95
Market cap
7.13M4.56M13.89M21.97M4.08M
Enterprise value
3.17M3.18M3.16M21.56M10.4M
P/E ratio
-0.62-0.69-1.69-1.26-0.15
Price to sales ratio
5.63-81.5179.62343.8713.36
POCF ratio
-0.54-0.54-2.87-1.61-0.47
PFCF ratio
-0.47-0.4-1.94-1.29-0.38
P/B Ratio
1.950.760.831.73-0.49
PTB ratio
1.950.760.831.73-0.49
EV to sales
2.51-56.7918.09337.4834.02
Enterprise value over EBITDA
-0.29-0.44-0.6-1.27-0.4
EV to operating cash flow
-0.24-0.38-0.65-1.58-1.2
EV to free cash flow
-0.21-0.28-0.44-1.27-0.96
Earnings yield
-1.61-1.45-0.59-0.79-6.5
Free cash flow yield
-2.12-2.5-0.52-0.77-2.65
Debt to equity
0.3900.030.05-0.76
Debt to assets
0.1500.030.031
Net debt to EBITDA
0.360.192.030.02-0.24
Current ratio
1.331.043.830.770.14
Interest coverage
-10.24-253.57-39.09-90.14-28.66
Income quality
1.151.270.590.790.33
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
3.37-70.2514.8776.6411.52
Research and developement to revenue
5.28-59.3816.41139.9364.39
Intangibles to total assets
0.360.730.440.760.62
Capex to operating cash flow
0.140.360.480.240.25
Capex to revenue
-1.4953.9-13.27-52.06-7.01
Capex to depreciation
-26.01-97.93-115.55-43.56-18.02
Stock based compensation to revenue
0.02-4.052.1118.881.12
Graham number
772.93206.33184.98106.4577.35
ROIC
-2.19-1.17-0.3-1.2417.16
Return on tangible assets
-1.81-2.7-0.7-3.84-11.01
Graham Net
-15.94-3.41K-571.31-6.08-15.4
Working capital
1.5M95.8K8.59M-1.1M-11.11M
Tangible asset value
114.41K-729.48K7.65M-1.61M-12.21M
Net current asset value
-162.35K-816.15K7.59M-2.37M-12.85M
Invested capital
0.3900.030.05-0.76
Average receivables
280.83K327.84K208.08K510.22K851.05K
Average payables
1.52M1.39M850.35K2.15M4.16M
Average inventory
-79.94K-494.29M-673.33M-178.67M425.43K
Days sales outstanding
92.37-2.19K169.165.37K910.68
Days payables outstanding
000577.41.21K
Days of inventory on hand
000136.712.94
Receivables turnover
3.95-0.172.160.070.4
Payables turnover
0000.630.3
Inventory turnover
0002.67124
ROE
-3.15-1.1-0.49-1.373.19
Capex per share
-47.57-20.75-7.7-5.02-2.35

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2021-06-302021-12-312022-06-302022-12-31 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
00000
Operating cash flow per share
00000
Free cash flow per share
00000
Cash per share
00000
Book value per share
00000
Tangible book value per share
00000
Share holders equity per share
00000
Interest debt per share
00000
Market cap
00000
Enterprise value
-8.47M-408.46K4.85M6.32M3.42M
P/E ratio
00000
Price to sales ratio
00000
POCF ratio
00000
PFCF ratio
00000
P/B Ratio
00000
PTB ratio
00000
EV to sales
00000
Enterprise value over EBITDA
00000
EV to operating cash flow
00.08000
EV to free cash flow
00.12000
Earnings yield
00000
Free cash flow yield
00000
Debt to equity
00.050.68-0.76-1.9
Debt to assets
00.030.2810.56
Net debt to EBITDA
00000
Current ratio
2.980.770.20.140.32
Interest coverage
00000
Income quality
0-0.56000
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
0.610.760.860.620.63
Capex to operating cash flow
0-0.35000
Capex to revenue
00000
Capex to depreciation
0-37.99000
Stock based compensation to revenue
00000
Graham number
00000
ROIC
00000
Return on tangible assets
00000
Graham Net
00000
Working capital
6.08M-1.1M-7.86M-11.11M-3.64M
Tangible asset value
5.54M-1.61M-8.18M-12.21M-5.72M
Net current asset value
5.5M-2.37M-8.88M-12.85M-6.3M
Invested capital
00.050.68-0.76-1.9
Average receivables
00000
Average payables
00000
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
00000
Capex per share
00000

EARS Frequently Asked Questions

What is Altamira Therapeutics Ltd. stock symbol ?

Altamira Therapeutics Ltd. is a CH stock , located in Zug of Zug and trading under the symbol EARS

What is Altamira Therapeutics Ltd. stock quote today ?

Altamira Therapeutics Ltd. stock price is $3.045 today.

Is Altamira Therapeutics Ltd. stock public?

Yes, Altamira Therapeutics Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Same Sector
Similar Market Cap